Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck cancer according to the National Cancer Data Base
- PMID: 26969811
- DOI: 10.1002/cncr.29956
Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck cancer according to the National Cancer Data Base
Abstract
Background: The overall survival (OS) benefit of concurrent chemoradiotherapy (CRT) for head and neck squamous cell carcinoma patients older than 70 years is debated. This study examines the outcomes of elderly patients receiving CRT versus radiotherapy (RT) alone.
Methods: The National Cancer Data Base was queried for patients older than 70 years with nonmetastatic oropharyngeal, laryngeal, or hypopharyngeal cancer (T3-4 or N(+)). CRT was defined as chemotherapy started within 14 days of the initiation of RT. Univariate analysis, multivariate analysis (MVA), propensity score matching (PSM), and recursive partitioning analysis (RPA) were performed.
Results: The study included 4042 patients: 2538 (63%) received CRT. The median follow-up was 19 months. The unadjusted median OS was longer with the addition of CRT (P < .001). OS was superior with CRT in the MVA (hazard ratio [HR], 0.63; 95% confidence interval [CI], 0.58-0.68; P < .001) and PSM analyses (HR, 0.73; 95% CI, 0.66-0.80; P < .001) in comparison with RT alone. According to RPA, CRT was associated with longer OS for patients 81 years or younger with low comorbidity scores and either T1-2/N2-3 disease or T3-4/N0-3 disease. The survival benefit with CRT disappeared for 2 subgroups in the 71- to 81-year age range: those with T1-2, N1, and Charlson-Deyo 0-1 (CD0-1) disease and those with T3-4, N1+, and CD1+ disease. Patients who were older than 81 years did not have increased survival with CRT. The receipt of CRT was associated with a longer duration of RT (odds ratio, 1.74; 95% CI, 1.50-2.01; P < .001).
Conclusions: Patients older than 70 years should not be denied concurrent chemotherapy solely on the basis of age; additional factors, including the performance status and the tumor stage, should be taken into account. Cancer 2016;122:1533-43. © 2016 American Cancer Society.
Keywords: National Cancer Data Base (NCDB); chemoradiation; concurrent chemoradiotherapy; elderly; head and neck squamous cell carcinoma (HNSCC); older.
© 2016 American Cancer Society.
Similar articles
-
Adjuvant Chemoradiation After Surgical Resection in Elderly Patients With High-Risk Squamous Cell Carcinoma of the Head and Neck: A National Cancer Database Analysis.Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):784-792. doi: 10.1016/j.ijrobp.2017.03.019. Epub 2017 Mar 18. Int J Radiat Oncol Biol Phys. 2017. PMID: 28602410
-
Impact of concomitant chemoradiation on survival for patients with T1-2N1 head and neck cancer.Cancer. 2017 May 1;123(9):1555-1565. doi: 10.1002/cncr.30508. Epub 2016 Dec 21. Cancer. 2017. PMID: 28001302
-
High-dose or low-dose cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer.Head Neck. 2017 Jul;39(7):1364-1370. doi: 10.1002/hed.24763. Epub 2017 Mar 28. Head Neck. 2017. PMID: 28370614
-
The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis.Cancer Res Treat. 2016 Jul;48(3):907-16. doi: 10.4143/crt.2015.359. Epub 2015 Nov 17. Cancer Res Treat. 2016. PMID: 26582394 Free PMC article. Review.
-
Survival outcomes for head and neck cancer patients with N3 cervical nodal metastases.Clin Otolaryngol. 2020 May;45(3):342-349. doi: 10.1111/coa.13501. Epub 2020 Feb 20. Clin Otolaryngol. 2020. PMID: 31869000
Cited by
-
Phase II trial of individualized/dynamic cisplatin regimens for definitive concurrent chemoradiation therapy in patients with head and neck squamous cell carcinoma.Cancer Med. 2020 Dec;9(24):9256-9265. doi: 10.1002/cam4.3529. Epub 2020 Oct 19. Cancer Med. 2020. PMID: 33073917 Free PMC article. Clinical Trial.
-
Treatment Outcomes and the Safety of Chemoradiotherapy With High-Dose CDDP for Elderly Patients With Head and Neck Squamous Cell Carcinoma: A Propensity Score Matching Study.Front Surg. 2021 Nov 23;8:753049. doi: 10.3389/fsurg.2021.753049. eCollection 2021. Front Surg. 2021. PMID: 34888343 Free PMC article.
-
Survival analysis of patients with advanced hypopharyngeal cancer comparing patients who received primary surgery to those who received chemoradiation: An analysis of the NCDB.Oral Oncol. 2021 Oct;121:105470. doi: 10.1016/j.oraloncology.2021.105470. Epub 2021 Aug 18. Oral Oncol. 2021. PMID: 34418696 Free PMC article.
-
Treatment with (chemo)-radiation in old patients (≥76 years of age) with newly diagnosed non-metastatic squamous cell cancer of the head and neck region: real-world data from a tertiary referral center.Front Oncol. 2024 Apr 25;14:1382405. doi: 10.3389/fonc.2024.1382405. eCollection 2024. Front Oncol. 2024. PMID: 38725619 Free PMC article.
-
Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients ≥65 years old.Radiat Oncol. 2017 Sep 9;12(1):150. doi: 10.1186/s13014-017-0878-9. Radiat Oncol. 2017. PMID: 28888224 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous